Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $16.19

Y-mAbs Therapeutics, Inc. (NASDAQ:YMABGet Free Report) shares gapped down prior to trading on Tuesday . The stock had previously closed at $16.19, but opened at $15.52. Y-mAbs Therapeutics shares last traded at $14.99, with a volume of 58,710 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on YMAB shares. BMO Capital Markets upped their price target on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the stock an “outperform” rating in a research note on Monday, March 4th. HC Wainwright increased their price objective on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Canaccord Genuity Group upped their target price on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a report on Monday, March 4th. Finally, Wedbush restated an “outperform” rating and issued a $18.00 target price (up from $12.00) on shares of Y-mAbs Therapeutics in a report on Monday, February 12th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $16.57.

Get Our Latest Analysis on YMAB

Y-mAbs Therapeutics Trading Down 2.3 %

The company’s fifty day moving average price is $15.32 and its two-hundred day moving average price is $9.41.

Y-mAbs Therapeutics (NASDAQ:YMABGet Free Report) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.17. The firm had revenue of $23.36 million for the quarter, compared to analyst estimates of $21.72 million. Y-mAbs Therapeutics had a negative net margin of 25.26% and a negative return on equity of 20.72%. As a group, research analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.43 earnings per share for the current year.

Insider Buying and Selling at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, SVP Vignesh Rajah sold 1,711 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $16.53, for a total transaction of $28,282.83. Following the transaction, the senior vice president now directly owns 33,889 shares of the company’s stock, valued at $560,185.17. The sale was disclosed in a filing with the SEC, which is available at this link. 21.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Y-mAbs Therapeutics

A number of hedge funds have recently made changes to their positions in YMAB. Tower Research Capital LLC TRC raised its stake in shares of Y-mAbs Therapeutics by 924.1% during the first quarter. Tower Research Capital LLC TRC now owns 5,899 shares of the company’s stock valued at $30,000 after purchasing an additional 5,323 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Y-mAbs Therapeutics during the fourth quarter valued at approximately $34,000. Russell Investments Group Ltd. raised its stake in shares of Y-mAbs Therapeutics by 1,347.5% during the first quarter. Russell Investments Group Ltd. now owns 11,812 shares of the company’s stock valued at $59,000 after purchasing an additional 10,996 shares during the period. Lazard Asset Management LLC purchased a new stake in shares of Y-mAbs Therapeutics during the third quarter valued at approximately $67,000. Finally, Graham Capital Management L.P. bought a new stake in shares of Y-mAbs Therapeutics in the second quarter worth $68,000. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

(Get Free Report)

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

Recommended Stories

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.